Nimble Science and KGK Science have signed a Letter of Intent to leverage their expertise and product offerings to build a stronger proposition in the market related to their respective business offerings.
London, Ontario, March 11, 2025 / Globe Newswire / – KGK Science, the leading North American contract research organization (CRO) focused on designing and conducting clinical trials as well as offering regulatory strategies for North American market access, compliance consultation, and preclinical services, announces, a new partnership with Nimble Science, a digital health company delivering precision GI insights via the SIMBA™ GI Platform. This collaboration aims to set a new standard for non-invasive gastrointestinal sampling in clinical research, leveraging Nimble Science’s advanced capsule sampling technology designed to collect endoscopic-quality intestinal fluid biopsies and KGK’s 28+ years history in delivering clinical trials on dietary supplements, nutraceuticals and food ingredients.
The signed Letter of Intent enables both organizations to deliver cutting-edge technology options for clinical studies aimed at evaluating GI health.
Transforming GI Health Research
The partnership between KGK Science and Nimble Science will re-imagine future biomarkers for GI health as this state-of-the-art technology opens new avenues for how GI studies can be conducted in the future.
“KGK Science is a leader in conducting clinical trials and helping companies gain market access and market distinction. We have vast experience in conducting clinical trials for probiotics and nutraceutical food ingredients with GI health outcomes over the past 28 years.” says Najla Guthrie, Chief Executive Officer at KGK Science.
“By integrating Nimble Science’s revolutionary SIMBA™ capsule technology, we can offer a state-of-the-art method for evaluating GI health outcomes in clinical trials, reducing the need for invasive biopsies”.
“Nimble Science aims to be the leading global collaborator in delivering actionable intelligence from the GI tract. Our SIMBA™ platform and capsule technology is transformative for conducting clinical trials in the area of GI health,” added Dr. Sabina Bruehlmann, CEO of Nimble Science. “This partnership with KGK Science is a major step toward our goal to transform global markets related to GI health research.”
A Game-Changer for the Probiotics and Nutraceutical Industry
This partnership enables companies developing probiotics, dietary ingredients, and functional foods to access more advanced and reliable clinical trial methodologies, supporting stronger regulatory submissions and market differentiation. Companies looking to validate GI health claims using cutting-edge clinical research are encouraged to connect with KGK Science to explore how this partnership can support their product development and regulatory goals.
ABOUT NIMBLE SCIENCE
Nimble is a digital health company delivering precision GI insights via the SIMBA GI Platform, leveraging advanced capsule sampling technology that collects endoscopic quality intestinal fluid biopsies (the “Capsules”) analyzed against a comprehensive database of reference samples (the “SIMBA GI Platform”). Nimble is seeking marketing and utilization support of their SIMBA Platform in global jurisdictions to serve customers interested in furthering their research and development activities utilizing intestinal fluid biopsies.
ABOUT KGK SCIENCE
KGK Science is the leading North American contract research organization based in London, Ontario, offering clinical trials, regulatory compliance consulting, and preclinical services primarily for the nutraceutical, dietary supplement, conventional food, and cosmetic industries. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK Science has helped companies gain lawful access and entry to North American markets with expert regulatory experience regulatory compliance consultation support, market access strategies, and preclinical research services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 35,000 participants in its database and collected over 10 million data points. For additional information, please visit www.kgkscience.com
On behalf of:
Najla Guthrie
Chief Executive Officer
KGK Science
For further information, please contact:
Anusri Nair
Marketing Manager
Email: anair@kgkscience.com
X (formerly Twitter) Handle: @KGKScience
Website: https://www.kgkscience.com
Sabina Bruehlmann
CEO
Nimble Science
Email: info@nimblesci.com
Website: http://www.nimblesci.com
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
